

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number  
**WO 2004/048350 A2**

(51) International Patent Classification<sup>7</sup>: **C07D 263/00**

(21) International Application Number:  
PCT/GB2003/005091

(22) International Filing Date:  
24 November 2003 (24.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0227704.4 28 November 2002 (28.11.2002) GB  
0310828.9 10 May 2003 (10.05.2003) GB

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GRAVESTOCK, Michael, Barry** [GB/US]; AstraZeneca R & D Boston,

35 Gatehouse Drive, Waltham, MA 02451 (US). **HALES, Neil, James** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **RECK, Folkert** [DE/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, MA 02451 (US). **ZHOU, Fei** [CA/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, MA 02451 (US).




(74) Agent: **ASTRAZENECA**; Global Intellectual Property, P.O. Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: **CHEMICAL COMPOUNDS**



(57) Abstract: A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: Wherein C is selected from (D) and (E), R<sub>2a</sub>, R<sub>6a</sub>, and R<sub>3a</sub> are independently selected from for example H, CF<sub>3</sub>, Me and Et; R<sub>2b</sub> and R<sub>6b</sub> are independently selected from for example H, F, CF<sub>3</sub>, Me and Et; R<sub>1b</sub> is for example optionally substituted diazoly, triazoly or tetrazoly; R<sub>4</sub> is for example an optionally substituted 5- or 6-membered heterocyclic ring system. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.



WO 2004/048350 A2